Scott M. Gilbert, MD

Where You Are:
Scott M. Gilbert, MD

Associate Member

Education And Training
  • Fellow, University of Michigan Health Systems, 2008 - Urology, Urology Oncology, Health Services Research Fellow
  • MS, University of Michigan, School of Public Health, 2007 - Clinical Research Design and Statistical Analysis
  • Resident, New York-Presbyterian Hospital Columbia University Medical Center, 2005 - Urology
  • Intern, New York-Presbyterian Hospital Columbia University Medical Center, 2001 - Surgery
  • MD, Columbia University, College of Physicians & Surgeons, 2000

His research interests are in Health Services and Outcomes Research among patients with urologic malignancies. His previous work has focused on health scale development, integration of quality of life assessment into clinical practice settings, and evaluation of variation and quality of cancer care.


  • Gilbert SM, Dunn RL, Wittmann D, Montgomery JS, Hollingsworth JM, Miller DC, Hollenbeck BK, Wei JT, Montie JE. Quality of life and satisfaction among prostate cancer patients followed in a dedicated survivorship clinic. Cancer. 2015 May;121(9):1484-1491. Pubmedid: 25538017.
  • Gilbert SM. Revisiting structure, process, and outcome. Cancer. 2015 Feb;121(3):328-330. Pubmedid: 25339064.
  • Modh RA, Mulhall JP, Gilbert SM. Sexual dysfunction after cystectomy and urinary diversion. Nat Rev Urol. 2014 Aug;11(8):445-453. Pubmedid: 24980191.
  • Hu M, Jacobs BL, Montgomery JS, He C, Ye J, Zhang Y, Brathwaite J, Morgan TM, Hafez KS, Weizer AZ, Gilbert SM, Lee CT, Lavieri MS, Helm JE, Hollenbeck BK, Skolarus TA. Sharpening the focus on causes and timing of readmission after radical cystectomy for bladder cancer. Cancer. 2014 May;120(9):1409-1416. Pubmedid: 24477968.
  • Gilbert SM, Sanda MG, Dunn RL, Greenfield TK, Hembroff L, Klein E, Saigal CS, Pisters L, Michalski J, Sandler HM, Litwin MS, Wei JT. Satisfaction with information used to choose prostate cancer treatment. J Urol. 2014 May;191(5):1265-1271. Pubmedid: 24333514. Pmcid: PMC4283586.
  • Bryant CM, Dang LH, Stechmiller BK, Gilbert SM, Morris CG, Zlotecki RA. Treatment of Small Cell Carcinoma of the Bladder With Chemotherapy and Radiation after Transurethral Resection of a Bladder Tumor. Am J Clin Oncol. 2014 Feb. Pubmedid: 24517956.
  • Schroeck FR, Kaufman SR, Jacobs BL, Zhang Y, Weizer AZ, Montgomery JS, Gilbert SM, Strope SA, Hollenbeck BK. The impact of technology diffusion on treatment for prostate cancer. Med Care. 2013 Dec;51(12):1076-1084. Pubmedid: 24226306. Pmcid: PMC3916901.
  • Gilbert SM, Lai J, Saigal CS, Gore JL. Downstream complications following urinary diversion. J Urol. 2013 Sep;190(3):916-922. Pubmedid: 23499749.
  • Jacobs BL, Zhang Y, Schroeck FR, Skolarus TA, Wei JT, Montie JE, Gilbert SM, Strope SA, Dunn RL, Miller DC, Hollenbeck BK. Use of advanced treatment technologies among men at low risk of dying from prostate cancer. Jama. 2013 Jun;309(24):2587-2595. Pubmedid: 23800935. Pmcid: PMC3857348.
  • Gore JL, Gilbert SM. Improving bladder cancer patient care: a pharmacoeconomic perspective. Expert Rev Anticancer Ther. 2013 Jun;13(6):661-668. Pubmedid: 23773101.
  • Dahm P, Gilbert S. ACP Journal Club. Radical prostatectomy and observation did not differ for mortality in localized prostate cancer. Ann Intern Med. 2012 Oct;157(8):JC4-JC5. Pubmedid: 23070507.
  • Gilbert S. Editorial comment. Urology. 2012 Jun;79(6):1279. Pubmedid: 22521194.
  • Gilbert SM, Kuo YF, Shahinian VB. Prevalent and incident use of androgen deprivation therapy among men with prostate cancer in the United States. Urol Oncol. 2012 Mar;29(6):647-653. Pubmedid: 19926311. Pmcid: PMC2888908.
  • Lee CT, Mei M, Ashley J, Breslow G, O'Donnell M, Gilbert S, Lemmy S, Saxton C, Sagalowsky A, Sansgiry S, Latini DM. Patient resources available to bladder cancer patients: a pilot study of healthcare providers. Urology. 2012 Jan;79(1):172-177. Pubmedid: 21996109.
  • Gilbert SM, Penson D. Outcomes research in urology. World J Urol. 2011 Feb;29(1):1-2. Pubmedid: 21120504.
  • Gore JL, Lai J, Gilbert SM. Readmissions in the postoperative period following urinary diversion. World J Urol. 2011 Feb;29(1):79-84. Pubmedid: 21104414. Pmcid: PMC3024518.
  • Bradford TJ, Weizer AZ, Gilbert SM, Dunn RL, Wojno K, Shah R, Wood DP. Is residual neurovascular tissue on prostatectomy specimens associated with surgeon intent at nerve-sparing and postoperative quality of life measures?. Urol Oncol. 2010 Dec;28(5):487-491. Pubmedid: 19110450.
  • Shahinian VB, Kuo YF, Gilbert SM. Reimbursement policy and androgen-deprivation therapy for prostate cancer. N Engl J Med. 2010 Nov;363(19):1822-1832. Pubmedid: 21047226.
  • Evans B, Montie JE, Gilbert SM. Incontinent or continent urinary diversion: how to make the right choice. Curr Opin Urol. 2010 Sep;20(5):421-425. Pubmedid: 20616739.
  • Hedgepeth RC, Gilbert SM, He C, Lee CT, Wood DP. Body image and bladder cancer specific quality of life in patients with ileal conduit and neobladder urinary diversions. Urology. 2010 Sep;76(3):671-675. Pubmedid: 20451964.
  • Gilbert SM, Dunn RL, Hollenbeck BK, Montie JE, Lee CT, Wood DP, Wei JT. Development and validation of the Bladder Cancer Index: a comprehensive, disease specific measure of health related quality of life in patients with localized bladder cancer. J Urology. 2010 May;183(5):1764-1769. Pubmedid: 20299056.
  • Dahm P, Gilbert SM, Zlotecki RA, Guyatt GH. How to use an article about prognosis. J Urology. 2010 Apr;183(4):1303-1308. Pubmedid: 20171663.
  • Gilbert SM. Prostate cancer: seminal vesicle sparing: a continuing trend?. Nat Rev Urol. 2009 Sep;6(9):475-476. Pubmedid: 19727146.
  • Gilbert SM, Hollenbeck BK. Limitations of lymph node counts as a measure of therapy. J Natl Compr Canc Netw. 2009 Jan;7(1):58-61. Pubmedid: 19176206.
  • Weizer AZ, Gilbert SM, Roberts WW, Hollenbeck BK, Wolf JS. Tailoring technique of laparoscopic partial nephrectomy to tumor characteristics. J Urology. 2008 Oct;180(4):1273-1278. Pubmedid: 18707711.
  • Siu W, Daignault S, Miller DC, Dunn RL, Gilbert S, Weizer AZ, Ye Z, Hollenbeck BK. Understanding differences between high and low volume hospitals for radical prostatectomy. Urol Oncol. 2008 Sep;26(3):260-265. Pubmedid: 18452816.
  • Gilbert SM, Montie JE. Determining when to recommend continent urinary diversion. Can Urol Assoc J. 2008 Aug;2(4):407-409. Pubmedid: 18781217. Pmcid: PMC2532553.
  • Gilbert SM, Daignault S, Weizer AZ, Wei JT, Hollenbeck BK. The use of tumor markers in testis cancer in the United States: a potential quality issue. Urol Oncol. 2008 Aug;26(2):153-157. Pubmedid: 18312934.
  • Hollenbeck BK, Dunn RL, Wolf JS, Sanda MG, Wood DP, Gilbert SM, Weizer AZ, Montie JE, Wei JT. Development and validation of the convalescence and recovery evaluation (CARE) for measuring quality of life after surgery. Qual Life Res. 2008 Aug;17(6):915-926. Pubmedid: 18574712. Pmcid: PMC2700337.
  • Hollenbeck BK, Dunn RL, Gilbert SM, Strope S, Miller DC. Effects of laparoscopy on surgical discharge practice patterns. Urology. 2008 Jun;71(6):1029-1034. Pubmedid: 18336886.
  • Gilbert SM. Separating surgical quality from causality--gaining perspective in the debate on lymph node count and extent of lymphadenectomy. Cancer. 2008 Jun;112(11):2331-2333. Pubmedid: 18383514.
  • Gilbert SM. Shifting focus to cancer survivorship in prostate cancer: challenges and opportunities. Curr Opin Urol. 2008 May;18(3):326-332. Pubmedid: 18382244.
  • Gilbert SM, Dunn RL, Miller DC, Daignault S, Ye Z, Hollenbeck BK. Mortality after urologic cancer surgery: impact of non-index case volume. Urology. 2008 May;71(5):906-910. Pubmedid: 18372016.
  • Gilbert SM, Miller DC, Hollenbeck BK, Montie JE, Wei JT. Cancer survivorship: challenges and changing paradigms. J Urology. 2008 Feb;179(2):431-438. Pubmedid: 18076919. Pmcid: PMC2665172.
  • Gilbert SM. Reliable measurement in urology: room for improvement. Eur Urol. 2007 Jul;52(1):1-2. Pubmedid: 17467163.
  • Hollenbeck BK, Daignault S, Dunn RL, Gilbert S, Weizer AZ, Miller DC. Getting under the hood of the volume-outcome relationship for radical cystectomy. J Urol. 2007 Jun;177(6):2095-2099. Pubmedid: 17509295.
  • Gilbert SM, Wood DP, Dunn RL, Weizer AZ, Lee CT, Montie JE, Wei JT. Measuring health-related quality of life outcomes in bladder cancer patients using the Bladder Cancer Index (BCI). Cancer. 2007 May;109(9):1756-1762. Pubmedid: 17366596.
  • Hensle TW, Gilbert SM. A review of metabolic consequences and long-term complications of enterocystoplasty in children. Curr Urol Rep. 2007 Mar;8(2):157-162. Pubmedid: 17303022.
  • Gilbert SM, Lee CT. A case of T2 muscle-invasive bladder cancer treated with neoadjuvant chemotherapy. Nat Clin Pract Urol. 2006 Dec;3(12):675-679. Pubmedid: 17149384.
  • Gilbert SM, Murphy AM, Katz AE, Goluboff ET, Sawczuk IS, Olsson CA, Benson MC, McKiernan JM. Reevaluation of TNM staging of renal cortical tumors: recurrence and survival for T1N0M0 and T3aN0M0 tumors are equivalent. Urology. 2006 Aug;68(2):287-291. Pubmedid: 16904438.
  • Gilbert SM, Whitson JM, Mansukhani M, Buttyan R, Benson MC, Olsson CA, Sawczuk IS, McKiernan JM. Detection of carbonic anhydrase-9 gene expression in peripheral blood cells predicts risk of disease recurrence in patients with renal cortical tumors. Urology. 2006 May;67(5):942-945. Pubmedid: 16698354.
  • Gilbert SM, McKiernan JM. The role of bisphosphonates in preventing skeletal complications of hormonal therapy. Urol Clin North Am. 2006 May;33(2):191-9, vi. Pubmedid: 16631457.
  • Mitchell RE, Gilbert SM, Murphy AM, Olsson CA, Benson MC, McKiernan JM. Partial nephrectomy and radical nephrectomy offer similar cancer outcomes in renal cortical tumors 4 cm or larger. Urology. 2006 Feb;67(2):260-264. Pubmedid: 16461075.
  • Torres SM, Diaz SF, Nogueira SA, Jessen C, Polzin DJ, Gilbert SM, Horne KL. Frequency of urinary tract infection among dogs with pruritic disorders receiving long-term glucocorticoid treatment. J Am Vet Med Assoc. 2005 Jul;227(2):239-243. Pubmedid: 16047659.
  • Gilbert SM, Hensle TW. Metabolic consequences and long-term complications of enterocystoplasty in children: a review. J Urol. 2005 Apr;173(4):1080-1086. Pubmedid: 15758705.
  • Gilbert SM, Cavallo CB, Kahane H, Lowe FC. Evidence suggesting PSA cutpoint of 2.5 ng/mL for prompting prostate biopsy: review of 36,316 biopsies. Urology. 2005 Mar;65(3):549-553. Pubmedid: 15780374.
  • Murphy AM, Gilbert SM, Katz AE, Goluboff ET, Sawczuk IS, Olsson CA, Benson MC, McKiernan JM. Re-evaluation of the Tumour-Node-Metastasis staging of locally advanced renal cortical tumours: absolute size (T2) is more significant than renal capsular invasion (T3a). BJU Int. 2005 Jan;95(1):27-30. Pubmedid: 15638890.
  • Gilbert SM, McKiernan JM. Epidemiology of male osteoporosis and prostate cancer. Curr Opin Urol. 2005 Jan;15(1):23-27. Pubmedid: 15586025.
  • Gilbert SM, DeCastro GJ, Benson MC. Large multilocular Müllerian duct cyst presenting as pelvic mass. Urology. 2004 Aug;64(2):375. Pubmedid: 15302500.
  • Lowe FC, Gilbert SM, Kahane H. Evidence of increased prostate cancer detection in men aged 50 to 59: a review of 324,684 biopsies performed between 1995 and 2002. Urology. 2003 Dec;62(6):1045-1049. Pubmedid: 14665352.
  • Gilbert SM, Russo P, Benson MC, Olsson CA, McKiernan JM. The evolving role of partial nephrectomy in the management of renal cell carcinoma. Curr Oncol Rep. 2003 May;5(3):239-244. Pubmedid: 12667422.
  • Gilbert SM, Olsson CA, Benson MC, McKiernan JM. The role of intravenous zoledronic acid in the management of high-risk prostate cancer. Curr Opin Urol. 2003 Mar;13(2):133-135. Pubmedid: 12584473.
  • Gilbert SM, Veltri RW, Sawczuk A, Shabsigh A, Knowles DR, Bright S, O'Dowd GJ, Olsson CA, Benson MC, Sawczuk IS. Evaluation of DD23 as a marker for detection of recurrent transitional cell carcinoma of the bladder in patients with a history of bladder cancer. Urology. 2003 Mar;61(3):539-543. Pubmedid: 12639642.
  • Gilbert SM, Benson MC, McKiernan JM. Linkage disequilibrium between the androgen receptor gene CAG and GGC repeats in the African-American population. Curr Urol Rep. 2002 Jun;3(3):189-193. Pubmedid: 12084187.
  • Gilbert SM, Dunn RL, Wei JT. Re: Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer: C. W. Ryan, D. Huo, L. M. Demers, T. M. Beer and L. V. Lacerna. J Urol 2006; 176: 972-978. J Urol. 2007 Apr;177(4):1584-1585. Pubmedid: 17382782.
  • Strope SA, Wolf JS, Hafez KS, Dunn RL, Hollingsworth JM, Gilbert SM, Hollenbeck BK. Understanding the relationship between health care quality and the renal mass. Urol Oncol. 27(4):443-447. Pubmedid: 19573776.
  • Vogel B, Gilbert SM, Boylston Herndon J, Dahm P. Advanced topics in evidence-based urologic oncology: economic analysis. Urol Oncol. 29(4):454-461. Pubmedid: 21726796.
  • Weizer AZ, Shah RB, Lee CT, Gilbert SM, Daignault S, Montie JE, Wood DP. Evaluation of the prostate peripheral zone/capsule in patients undergoing radical cystoprostatectomy: defining risk with prostate capsule sparing cystectomy. Urol Oncol. 25(6):460-464. Pubmedid: 18047952.
TOOLS:   Font Size small font resizer separator font resizer separator big font resizer
 |  Site Map  |  Privacy Policy  |  Terms and Conditions